Navigation Links
Progentix Orthobiology B.V. Closes Series A Financing Round
Date:1/22/2008

BILTHOVEN, The Netherlands, January 22 /PRNewswire/ -- Progentix Orthobiology B.V. announced today the closure of its Series A financing Round. The round was led by BioGeneration Ventures.

Progentix Orthobiology B.V. was established in 2007 and develops a unique suite of osteoinductive material products for clinical application in bone regenerative surgery. Progentix bone graft material is based on surface structured ceramic biomaterial scaffolds that have the ability to attract growth factors and stems cells after implantation, which results in the induction of bone growth. These materials are not only superior to currently available synthetic ceramic bone grafts, but based on their bone healing and regeneration potential also directly compete with the gold standard of autologous bone, and the growth factors that are being used today and those under development. The Series A financing round will support further technology validation and the generation of clinical proof of principle.

Dr. Joost de Bruijn, CEO of Progentix Orthobiology said: "We are extremely pleased with the support of BioGeneration Ventures. This financing round will allow us to continue building value and lay the groundwork for the launch of our first products in the near future."

"We strongly believe in the high quality of the Progentix Orthobiology technology," says Edward van Wezel M.Sc., managing partner at BioGeneration Ventures BV. "This novel technology platform will address a real medical need in the area of bone grafts. The scientific team has an excellent track record in the development of biomaterials and tissue engineering." Dr. Clemens van Blitterswijk, professor in Tissue Regeneration at the University of Twente and former CEO of IsoTis N.V., and Edward van Wezel will join the board of directors of Progentix Orthobiology.

About Biogeneration Ventures BV

BioGeneration Ventures invests in Dutch Life Sciences companies. The team of BioGeneration is specialized in the evaluation of new technologies and in the management of start-up companies. BioGeneration Ventures was co-founded by the Netherlands Genomics Initiative (NGI), NWO, the holding of the University of Leiden, and ABN-AMRO Capital. BioGeneration closely cooperates with Forbion Capital Partners (http://www.forbion.com).

Contact:

Progentix Orthobiology B.V.

Prof. Dr. Joost de Bruijn

T: +31-30-2295234

E: info@progentix.com

W: http://www.progentix.com

BioGeneration Ventures B.V.

Edward van Wezel

T: +31-35-6993011

E: info@biogenerationventures.com

W: http://www.biogenerationventures.com


'/>"/>
SOURCE Progentix Orthobiology
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... 23, 2016 , ... Supplyframe, the Industry Network for electronics ... Lab . Located in Pasadena, Calif., the Design Lab’s mission is to bring ... designed, built and brought to market. , The Design Lab is Supplyframe’s physical ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
Breaking Biology News(10 mins):